Hong Guodai, Chen Xuemei, Sun Xizhuo, Zhou Meiling, Liu Bing, Li Zhu, Yu Zhendong, Gao Wenbin, Liu Tao
Department of Biotherapy and Oncology, Shenzhen Luohu People's Hospital, The Third Affiliated Hospital (The Affiliated Luohu Hospital) of Shenzhen University, Shenzhen 518001, China.
The Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China.
Precis Clin Med. 2019 Dec;2(4):235-245. doi: 10.1093/pcmedi/pbz023. Epub 2019 Nov 22.
This study investigated the efficiency of natural killer (NK) cell immunotherapy on non-small cell lung cancer with and without EGFR mutations in order to evaluate the response rate (RR) and progression-free survival (PFS). Among the 48 patients recruited, 24 were clinically confirmed to be EGFR mutation positive. The study group was treated with autologous NK cell immunotherapy. Comparisons of the lymphocyte number, serum tumour-related biomarkers, circulating tumour cells (CTC), Karnofsky Performance Status (KPS) and survival curves were carried out before and after NK cell immunotherapy. The safety and short-term effects were evaluated, followed by median PFS and RR assessments. The serum CEA and CA125 values were found lower in the NK cell therapy group than that of the non-NK treatment group (). The χ test showed a 75% RR of the study group A, significantly higher than that of the control group B (16.7%; ). The RR of groups C (58.3%) and D (41.7%) were not statistically significant. The values of the 4 groups were 0.012, 0.012, 0.166 and 1 from group A to group D, respectively. The median PFS was 9 months in EGFR mutation positive group undergoing NK cell infusion interference. By evaluating the changes in immune function, tumour biomarkers, CTC, KPS and PFS, we demonstrated that NK cell therapy had better clinical therapeutic effects on EGFR mutation-positive lung adenocarcinoma.
本研究调查了自然杀伤（NK）细胞免疫疗法对伴有和不伴有表皮生长因子受体（EGFR）突变的非小细胞肺癌的疗效，以评估缓解率（RR）和无进展生存期（PFS）。在招募的48例患者中，24例经临床确诊为EGFR突变阳性。研究组接受自体NK细胞免疫疗法治疗。在NK细胞免疫疗法前后，对淋巴细胞数量、血清肿瘤相关生物标志物、循环肿瘤细胞（CTC）、卡氏功能状态评分（KPS）和生存曲线进行了比较。评估了安全性和短期疗效，随后进行了中位PFS和RR评估。发现NK细胞治疗组的血清癌胚抗原（CEA）和糖类抗原125（CA125）值低于非NK治疗组（）。χ检验显示研究组A的RR为75%，显著高于对照组B（16.7%；）。C组（58.3%）和D组（41.7%）的RR无统计学意义。从A组到D组，4组的值分别为0.012、0.012、0.166和1。接受NK细胞输注干预的EGFR突变阳性组的中位PFS为9个月。通过评估免疫功能、肿瘤生物标志物、CTC、KPS和PFS的变化，我们证明NK细胞疗法对EGFR突变阳性的肺腺癌具有更好的临床治疗效果。
